Psoriatic Arthritis News You Can Use From EULAR 2022

What EULAR 2022 Was (and Why PsA Patients Should Care)

EULAR’s annual meeting is where rheumatology tries to do three things at once: compare new therapies, refine how we measure disease, and translate
research into practical care. In 2022, PsA discussions leaned hard into “whole-person outcomes”:
not just swollen joints, but skin clearance, enthesitis and dactylitis control, function, fatigue, and work productivity.

If you’ve ever felt like your psoriasis, joint pain, and fatigue were being treated as separate planets in separate solar systems,
EULAR 2022’s vibe was basically: “Let’s stop doing that.”

Theme #1: Raise the BarACR50, MDA, and Treat-to-Target

ACR50: the “that’s a real change” checkpoint

In PsA trials, you’ll often see ACR20, ACR50, and ACR70meaning 20%, 50%, or 70% improvement in a bundle of joint-related measures.
EULAR 2022 spotlighted studies that used ACR50 as a primary endpoint, which is a higher bar than the traditional “20% improvement”
threshold. Translation: researchers are increasingly asking therapies to prove they can deliver meaningful, noticeable improvement.

MDA: seven boxes, check five (and call it progress)

Minimal disease activity (MDA) is popular because it reflects PsA’s “multi-domain” reality. It’s not just joints; it also considers skin, pain,
function, and enthesitis. In plain English, MDA is a “low disease footprint” goal that tends to feel more real in everyday life than a single score.

One widely used MDA definition requires meeting 5 of 7 criteria (covering joints, skin, pain, function, patient global, and enthesitis). It’s a
structured way to answer: “Are we controlling most of what this disease is doing to you?”

Treat-to-target: the strategy that sounds boring… until it saves your joints

Treat-to-target means you and your clinician agree on a goal (ideally remission, or at least low disease activity) and adjust therapy until you reach it.
The Arthritis Foundation’s patient-friendly explanation is refreshingly direct: meds are adjusted over time to hit a predetermined goal. When remission
isn’t realistic, low disease activity is still a win worth planning for.

Theme #2: Newer Mechanisms, Better Multi-Domain Coverage

EULAR 2022 didn’t just celebrate “another biologic.” It highlighted approaches that aim to cover more PsA domains with one therapy
andimportantlymake the improvement obvious enough that your body notices before your calendar does.

Dual IL-17A/IL-17F blockade (bimekizumab): strong joint + skin results, with a familiar IL-17 “gotcha”

A major headline was phase 3 data for bimekizumab, which blocks IL-17A and IL-17Ftwo inflammatory signals implicated in psoriatic disease.
Two key trials were discussed:

• BE OPTIMAL: biologic DMARD–naïve PsA
• BE COMPLETE: PsA with inadequate response or intolerance to TNF inhibitors

In both studies, bimekizumab hit the primary endpoint of ACR50 at week 16. In BE OPTIMAL, about 43.9% of
bimekizumab-treated patients achieved ACR50 vs 10.0% on placebo. In BE COMPLETE, about 43.4% hit ACR50 vs
6.8% on placebo. That’s the kind of difference that makes graphs look like they’re yelling.

Skin outcomes also stood out. For patients with meaningful baseline skin involvement, high levels of clearance (like PASI90) were far more common
with bimekizumab than placebo, and a sizable portion of patients reached MDA by week 16 as well.

Safety looked broadly consistent with what clinicians already watch for in IL-17–pathway therapies. One recurring theme: fungal/yeast infections,
including Candida, occurred more often in the bimekizumab group than placebo in the EULAR materials. This doesn’t mean “don’t use IL-17 therapy,”
it means “use it like an adult”: screen, counsel, and manage risk thoughtfully.

IL-23 inhibition (guselkumab): long-run, multi-domain durabilityplus quality-of-life outcomes that feel “human”

Another EULAR 2022 spotlight: longer-term guselkumab data across multiple phase 3 programs, emphasizing durability across core PsA domainsjoints, skin,
enthesitis, dactylitis, and (for some) axial symptomsalong with patient-reported outcomes like fatigue and work productivity.

A particularly “news you can use” detail: in one set of EULAR-reported analyses, 40% of certain guselkumab-treated patients achieved
MDA by week 100, and DAPSA-based low disease activity and remission milestones were also reported in meaningful proportions.
Among people who had dactylitis or enthesitis at baseline, resolution rates increased over time and remained strong through longer follow-up windows.

Why this matters: PsA is notorious for leaving people with a technically improved joint countbut still exhausted, achy, and struggling at work.
EULAR 2022’s IL-23 story wasn’t just “less inflammation,” it was “less life disruption.”

Oral targeted therapy (upadacitinib): 2-year efficacy with careful safety framing

Oral therapies are popular because shots are not everyone’s love language. At EULAR 2022, 2-year results from a phase 3 upadacitinib program
reported sustained responses across joint and skin outcomes, MDA, and resolution of enthesitis/dactylitiswith comparisons versus adalimumab also reported.

The “useful” part: if you’re considering an oral JAK inhibitor, EULAR 2022 discussions reinforced two truths that can peacefully coexist:
(1) the efficacy can be strong and durable, and (2) safety conversations should be specific to the person in front of the clinicianespecially for
cardiovascular, clotting, and malignancy risks.

Theme #3: Domain-Based CareBecause PsA Doesn’t Stay in Its Lane

EULAR 2022 reinforced a practical idea: PsA treatment choices should reflect your dominant “domains.”
A person with raging enthesitis and mild skin may need a different strategy than someone with dramatic psoriasis and moderate joints.
And someone with possible axial involvement has yet another set of priorities.

What changed in 2022 wasn’t that clinicians suddenly discovered domains (they’ve known), but that more trial readouts started to feel “domain-native”:
enthesitis resolution rates, dactylitis outcomes, skin clearance benchmarks, function measures, radiographic progression, and patient-reported burdens.

For patients, this is empowering because it gives you language beyond “I hurt.” You can walk in and say:
“My enthesitis is what’s crushing my day,” or “My dactylitis makes typing miserable,” or “My skin and fatigue are the dealbreakers.”

Theme #4: Quality of Life Is Finally Getting Top Billing

PsA is not just inflammatory arthritis plus a skin condition. It’s also sleep disruption, mood effects, social friction, and that uniquely annoying
fatigue that makes you feel like your bones are buffering.

EULAR 2022 reporting placed more emphasis on outcomes like fatigue, pain improvement, physical function (HAQ-DI), and work productivity.
This matters because two patients can have the same joint count and wildly different lives.

What you can track (even if you hate spreadsheets)

• Fatigue: “How wrecked am I by 2 p.m.?” (0–10 works fine.)
• Function: grip, stairs, morning stiffness time, typing endurance.
• Flares: what triggers them (stress, infections, missed doses, sleep).
• Skin + nails: photos helpyour future self will thank you.

Theme #5: Safety Isn’t a FootnoteEspecially for Targeted Oral Therapies

EULAR 2022’s “useful news” included how clinicians are framing safety tradeoffs in 2022-era PsA care.
This is where nuance matters: risk is not a moral failing, and no therapy is “risk-free herbal moonlight.”

JAK inhibitors: effective, but the boxed-warning conversation is real

In the U.S., the FDA required updated warnings about increased risks (including serious heart-related events, cancer, blood clots, and death)
for certain JAK inhibitors used in chronic inflammatory conditions. That context influences how clinicians discuss oral JAK options in PsAespecially for
patients with cardiovascular risk factors, a history of smoking, or prior malignancy concerns.

Practical takeaway: if an oral option is on the table, ask your clinician to walk you through your risk profile, not “the internet’s
risk profile.”

IL-17 pathway therapies: watch infections (including yeast)

IL-17 pathway treatments can be very effective for PsA and psoriasis, but the class is associated with particular infection patterns.
The EULAR 2022 bimekizumab materials, for example, highlighted Candida infections occurring more often in the treatment arm than placebo.
This is typically manageable, but it’s not something you want to discover by surprise at midnight with a pharmacy closed.

IL-23 inhibitors: long-term tolerability focus

Longer-term IL-23 data at EULAR emphasized sustained responses with an established safety profile in trials, plus ongoing monitoring.
As always, discuss infection risk, vaccines, and comorbidities with your care team.

Questions to Ask Your Rheumatologist (EULAR 2022-Inspired)

• Targets: “Are we aiming for remission, MDA, or low disease activityand how will we measure it?”
• Domains: “Which domain is driving my disease burden right nowjoints, skin, enthesitis, spine, fatigue?”
• Timeline: “When do we reassess, and what counts as ‘working’?”
• Safety: “Given my personal risks, what side effects should I watch for and how do we prevent them?”
• Plan B: “If I don’t hit target, what’s the next stepswitch, add-on, dose change?”

Bonus move: bring a one-page “symptom receipt.” Dates, photos, and a short list of what you can’t do right now.
Clinicians love data; your joints are already generating plentymight as well invoice it properly.

Real-World Experiences: What EULAR 2022 “News” Looks Like in Daily Life (Extra )

Here’s the part most conference slides can’t show: the lived experience behind the endpoints. When you hear “ACR50” or “MDA,” it’s tempting to imagine
a tidy before-and-after montage. In reality, PsA progress often looks like a messy renovation: you live in the house while the work is happening.

Experience #1: The ‘I thought it was just stress’ detour. A common story starts with intermittent joint pain, a few swollen fingers,
heel pain that makes mornings feel like stepping on Lego, and fatigue that could nap through a fire alarm. Skin symptoms might be obviousor subtle
enough that nobody connects the dots. EULAR’s focus on domain-based care matters here because getting the diagnosis early and naming the domains
(enthesitis! dactylitis! possible axial involvement!) can shorten the “it’s probably nothing” loop.

Experience #2: The treat-to-target negotiation. Treat-to-target sounds straightforward: set a goal, adjust meds, repeat.
But patients are humans, not spreadsheets. People worry about side effects, costs, switching away from a drug that’s “kind of working,” and the emotional
tax of starting over. Patient-facing reporting around EULAR highlighted that even when people trust their rheumatologist, they may still be hesitant to
add or switch DMARDs because the tradeoffs feel personal: pain while waiting for a new med to kick in, uncertainty of response, and fear of new risks.
If you’ve ever stared at a medication brochure and thought, “This seems like a lot of ‘possible’,” congratulationsyou are literate.

Experience #3: When skin and joints don’t synchronize their calendars. Some patients get beautiful skin clearance while joints keep
smoldering. Others get calmer joints while psoriasis remains loud. EULAR 2022’s multi-domain emphasis is a reminder that “better” isn’t always “enough,”
and it’s okay to say: “My joints are improved, but fatigue is still stealing my afternoons,” or “My skin is better, but enthesitis makes walking
miserable.” Those are not complaints; they’re clinical information.

Experience #4: The safety talk that shouldn’t feel like a scare talk. The U.S. boxed-warning conversation around JAK inhibitors can
sound alarming online, but in the clinic it’s usually more precise: your clinician reviews cardiovascular risks, clot history, age, smoking status,
cancer history, and other factors. Many patients find the most helpful framing is: “What’s my baseline risk, how does this change it, and what can we do
to monitor or reduce risk?” That turns fear into a plan.

Experience #5: Small wins are still wins. “Minimal disease activity” doesn’t mean you feel like a superhero. It can mean you can open
a jar without bracing for impact, walk the grocery store without bargaining with your ankles, or finish a workday without the brain-fog crash.
EULAR 2022’s push toward higher targets is encouragingbut it also validates the incremental improvements that make life more livable.

If there’s one “news you can use” lesson that survives the trip from conference hall to real life, it’s this:
PsA care works best when you treat it like a partnershipmeasuring what matters, adjusting when needed, and making decisions that fit your body and your
life, not just the average patient in a trial.